Drug Database
FE

fexofenadine + pseudoephedrine

✓ Approved

RVL Pharmaceuticals · HRH1 · 小分子

什么是 fexofenadine + pseudoephedrine?

fexofenadine + pseudoephedrine 是一种小分子,由RVL Pharmaceuticals研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

公司RVL Pharmaceuticals
药物类别小分子
分子靶点HRH1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

fexofenadine + pseudoephedrine 作用于 1 个分子靶点:

HRH1histamine receptor H1 (HH1R, H1R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

fexofenadine + pseudoephedrine 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersUrticaria✓ Approved
Immune system disordersSeasonal allergy✓ Approved

相关研究文献

PubMedCurrent pharmaceutical design2026-11-13

Degradation-Driven Implications for the Pharmacology and Risk Profile of Fexofenadine.

Prado Camila Carlos CC, Sa Filho Alberto Souza AS, Ogbu John Ihayi JI, de Lima Moreira Caroline Vitoria CV et al.

Understanding a drug's degradation profile is essential for ensuring its stability, efficacy, and safety. This minireview summarizes the pharmacological characteristics of fexofenadine and predicts its degradation pathways, with an emphasis on quality assessment and regulatory implications. To build on the outlined objectives, a systematic search was conducted in PubMed and Scopus using keywords related to fexofenadine's pharmacology, chemical structure, and degradation mechanisms. Of 368 records identified, 52 studies met the inclusion criteria and were critically analyzed. Following this analysis, it was found that fexofenadine is susceptible to photolysis, hydrolysis, and N-nitrosation processes. Fexofenadine's vulnerabilities, which are corroborated by forced degradation studies, may compromise its stability and lead to nitrosamine formation. Notably, the drug is primarily excreted unchanged, indicating minimal metabolic transformation. Predicted metabolic routes include aromatic hydroxylation, Ndealkylation, and piperidine ring opening; however, its high polarity favors renal elimination. Phase II conjugation, particularly glucuronidation, may further contribute to its clearance and the absence of detectable metabolites. In addition, nanoformulations have been shown to enhance fexofenadine's stability, bioavailability, and therapeutic performance. Further investigation into fexofenadine's stability is critical for optimizing formulation strategies, guiding quality control, and mitigating degradation-related risks. Theoretical and experimental insights can strengthen regulatory compliance and ensure sustained drug safety.

PMID 43021078
阅读全文 →
PubMedJournal of biomolecular structure & dynamics2026-11-10

Integrated molecular modeling and in vitro validation identify new acetylcholinesterase-inhibitory scaffolds among FDA-approved drugs.

Kumar Ram R, Das Modak Sanjib S, Babu M Arockia MA, Sinha Suman S

Acetylcholinesterase (AChE) inhibition remains a clinically validated strategy for the symptomatic management of Alzheimer's disease (AD). However, the limited long-term efficacy of currently available inhibitors continues to drive the search for new scaffolds, making drug repurposing an attractive strategy for accelerating drug discovery. Here, an integrated structure-guided workflow combining molecular docking, molecular dynamics (MD) simulations, MMGBSA binding free-energy analysis, dynamic interaction profiling, and in vitro enzyme inhibition assays was employed to investigate the AChE inhibitory potential of FDA-approved drugs. The docking study identified lumacaftor, olaparib, fexofenadine, and vibegron as the highest-ranked compounds, while MMGBSA predicted favourable binding energetics for lumacaftor, pemetrexed, olaparib, and cilostazol. MD simulations showed that most of the compounds remained favourably accommodated within the AChE active-site gorge while maintaining overall structural integrity of the enzyme. In vitro enzyme inhibition assays identified olaparib, cilostazol, and miconazole with the lowest measured IC50 values (2.86, 2.88, and 2.89 μM, respectively), while vibegron, irbesartan, pemetrexed, lumacaftor, and indomethacin also showed measurable inhibition. Fexofenadine showed 51.26 ± 4.81% inhibition at 20 μM, but its IC50 was not determined. Differences between computational predictions and experimental activity highlight the utility of computational approaches for compound prioritization rather than quantitative prediction of biological activity. Taken together, this study identified FDA-approved drugs with, to the best of our knowledge, previously unreported AChE inhibitory activity and provided mechanistic insights into AChE-ligand recognition. These compounds represent preliminary, experimentally supported AChE-interacting scaffolds for further biochemical, pharmacological, and in vivo investigation.

PMID 43007886
阅读全文 →
PubMedChemistry (Weinheim an der Bergstrasse, Germany)2026-11-05

Total Synthesis and Absolute Configuration of the Irregular Tetraterpene Viaticene A.

Stamm Patrick P, Solak Ozan O, Kuhn Johanna J, Schulz Stefan S

Viaticenes are tetraterpenes with a unique [6+2]-connectivity known from the epicuticular lipid layer of the springtail Hypogastrura viatica. Here, we report the total synthesis of viaticene A in thirteen steps from methyl 5-hexynoate, with an overall yield of 16%. Key steps in the construction of the core fragment include the stereoselective introduction of the E- and Z-double bonds via silyl- and carbocupration, respectively, and establishment of the central stereogenic center using pseudoephedrine as a chiral auxiliary. Subsequently, C9- and C11-alkyl building blocks are coupled to the core fragment via copper-mediated allylic substitution and nickel/cobalt-cocatalyzed vinyl-alkyl cross-electrophile coupling, preventing double-bond migration in the latter reaction with the novel additive combination styrene/water/molecular sieves. The modular synthesis route gives selective access to relevant diastereomers, allowing determination of the absolute configuration of viaticene A. Configurations at C-3, C-7, and C-19 are elucidated through careful analysis of the 13C-NMR spectra, assigning the all-R-configuration to the natural product.

PMID 42983587
阅读全文 →
PubMedBMC chemistry2026-10-22

Eco-sustainable organic solvent-free spectrophotometric method for the concurrent determination of a ternary pharmaceutical mixture.

Hamdy Abdallah M AM, Meselhy Esraa M EM, El Henawee Magda M MM, Hashem Hisham H et al.

In recent years, green analytical chemistry has become essential in pharmaceutical research, aiming to mitigate environmental hazards associated with conventional analytical practices. The current focus lies in optimizing analytical methods to achieve both environmental and economic sustainability. In this framework, three environmentally sustainable spectrophotometric methods were developed for simultaneous analysis of three co-formulated drugs: acetaminophen, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride, which are often used to alleviate symptoms associated with COVID-19. The employed spectrophotometric methodologies include the double divisor-ratio spectra derivative method, the mean centering of double divisor ratio spectra method, and the dual wavelength in ratio spectrum method. The innovative techniques displayed good linearity within 25-350 µg/mL for dextromethorphan hydrobromide, 2-24 µg/mL for acetaminophen, and 100-1400 µg/mL for pseudoephedrine hydrochloride. The environmental sustainability of the proposed methods was evaluated using the Analytical Eco-Scale, analytical greenness metric, and the Green Analytical Procedure Index. Furthermore, complementary evaluations of blueness and whiteness were conducted through the Blue Applicability Grade Index and the Red Green Blue 12 metric, respectively. The collective outcomes of all evaluation metrics clearly demonstrated that the proposed methods possess enhanced environmental compatibility and sustainability relative to the existing techniques. The proposed methods were fully validated according to the International Conference on Harmonization recommendations. The developed methods offered a cost-effective and eco-friendly approach for concurrent determination of acetaminophen, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride in their bulk substances, and pharmaceutical formulations.

PMID 42907898
阅读全文 →
PubMedThe Journal of allergy and clinical immunology2026-10-16

Comparative efficacy and safety of antihistamines, increased antihistamine dosing (updosing), and antihistamine adjuncts for chronic urticaria: Systematic review, dose-response, and network meta-analysis of randomized trials.

Chu Alexandro W L AWL, Zhao Irene X IX, Rayner Daniel G DG, Guyatt Gordon H GH et al.

Chronic urticaria, an immune-mediated condition characterized by wheals, angioedema, or both lasting for more than 6 weeks, is treated with H1 antihistamines as the first-line therapy. Questions remain regarding the comparative benefits and harms of antihistamines and their adjuncts, and of H1 antihistamine dose escalation. We analyzed the comparative benefits and harms of antihistamines and their adjuncts (H2 blockers or montelukast) as well as of H1 antihistamine dose escalation. As part of updating the American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma & Immunology Joint Task Force on Practice Parameters Chronic Urticaria guidelines, we searched MEDLINE, EMBASE, CENTRAL, and regulatory databases from inception to March 17, 2025, for randomized trials addressing antihistamines or their adjuncts for chronic urticaria. Paired reviewers independently screened records, extracted data, and assessed risk of bias. Random effects network and dose-response meta-analyses addressed urticaria activity, angioedema activity, urticaria-related quality of life, and harms including sedation. The GRADE approach informed certainty of evidence ratings. CRD42022367280. A total of 211 trials (22,187 participants) evaluated 55 unique treatments. Bilastine, desloratadine, and fexofenadine are among the most effective in overall improvement. Cetirizine and loratadine are among the most effective in reducing overall urticaria activity and its subcomponents, with cetirizine also effective in improving urticaria-related quality of life. Second-generation agents may be more effective than first-generation agents in improving urticaria activity and sleep disturbance. Sedation risk likely increases with higher doses, with first-generation agents like diphenhydramine among the most sedating, while sedation risk differs among second-generation agents. For chronic urticaria, second-generation agents differ in their efficacy and safety. First-generation agents are less beneficial and more harmful. Escalating to higher daily doses may provide additional benefits but likely increases sedation.

PMID 42887704
阅读全文 →
PubMedThe American Journal of dermatopathology2026-10-15

Neutrophilic Fixed Drug Eruption Mimicking Neutrophilic Dermatosis: Two Cases, Including Sequential Biopsies Demonstrating Time-Dependent Histopathology.

Chamninawakul Padol P, Lim Ziying Vanessa ZV, Khoo Lawrence Shih Wee LSW, Lee Joyce Siong See JSS

Fixed drug eruption (FDE) is classically a lymphocyte-predominant interface dermatitis, but an early lesion may show a prominent neutrophilic infiltrate that closely simulates a primary neutrophilic dermatosis. We report 2 cases. The first, a 42-year-old woman, developed a multifocal eruption approximately 45 minutes after re-exposure to etoricoxib, recurring at previously affected and new sites. A punch biopsy performed 21 hours after ingestion of the drug showed a basketweave stratum corneum, intense papillary dermal edema with pseudovesiculation, and a superficial and deep infiltrate rich in neutrophils with karyorrhexis, closely resembling Sweet syndrome. Only occasional apoptotic keratinocytes were present within the epidermis, and the marked edema obscured any interface dermatitis, although admixed eosinophils were noted. Clinicopathologic correlation ultimately established the diagnosis of neutrophilic FDE. The second, a 55-year-old man, had an eruption recurring at the same sites after pseudoephedrine. A biopsy of an established lesion 2-3 weeks after ingestion showed classic interface dermatitis with numerous eosinophils and pigment incontinence, whereas one taken from the same region within 24 hours of re-exposure showed a neutrophil-predominant infiltrate with prominent karyorrhexis and only focal interface change. These cases, biopsied at documented time points, support the concept that the neutrophil-rich appearance of FDE represents an early phase in its histopathologic evolution, demonstrate how it can be mistaken for a neutrophilic dermatosis in the absence of adequate clinical history, and show that clinicopathologic correlation and a high index of suspicion are necessary to reliably arrive at the correct diagnosis.

PMID 42878618
阅读全文 →

注册免费账户还可查看另外 2681 篇文献

免费注册查看全部文献 →

了解更多fexofenadine + pseudoephedrine